PB1328 - The Venous Thrombosis Registry in Østfold Hospital (The TROLL registry); design and cohort description

Tuesday, July 12, 2022

6:30 PM – 7:30 PM

Location: Exhibition

Presentation Format: In-Person

Presenting Author(s)

Camilla Tøvik Jørgensen, PhD candidate

Ph.D student
Østfold Hospital
Sarpsborg, Ostfold, Norway

Co-Author(s)

MT

Mazdak Tavoly

MD, Ph.D
Sahlgrenska University Hospital, Gothenburg
Gothenburg, Vastra Gotaland, Sweden
HP

Heidi Hassel Pettersen

Nurse
Østfold Hospital
Sarpsborg, Ostfold, Norway
EF

Eli Førsund

Bachelor in nursing / study nurse
Østfold Hospital
Sarpsborg, Ostfold, Norway
CR

Christina Roaldsnes

M.sc / study coordinator
Østfold Hospital
Sarpsborg, Ostfold, Norway
MO

Magnus Kringstad Olsen

Researcher
Østfold Hospital
Sarpsborg, Ostfold, Norway
ET

Eirik Tjønnfjord

MD
Østfold Hospital
Sarpsborg, Ostfold, Norway
JG

Jostein Gleditsch

Consultant in Radiology
Consultant in Radiology
Fredrikstad, Ostfold, Norway
AG

Aleksandra Grdinic Galovic

MD Post doc
Østfold Hospital
Sarpsborg, Ostfold, Norway
SV

Synne Frønæs Vikum

MD Post doc
Clinic of Internal Medicine, Østfold Hospital, Norway and Institute for Clinical Medicine, University of Oslo, Norway
Oslo, Oslo, Norway
SB

Sigrid K. Brækkan, PhD

Professor
Thrombosis Research Center (TREC), Division of Internal Medicine, University Hospital of North Norway, Tromsø, Norway
Tromsø, Troms, Norway
Waleed Ghanima, MD

Professor
Østfold Hospital Foundation
Gralum, Ostfold, Norway

Background: The incidence of venous thromboembolism (VTE) is expected to increase over the next decades, further increasing its substantial impact on patients and health care resources. Registries have the benefit of reporting real-world data without excluding clinically important subgroups.

Aims: To describe a Norwegian VTE registry and to characterize the registered population.

Methods: The Venous Thrombosis Registry in ØstfOLd HospitaL (TROLL) is an ongoing registry of consecutive patients diagnosed with, treated and/or followed up for VTE at Østfold Hospital, Norway, since 2005. Baseline and follow-up data, including demography, clinical features, risk factors, diagnostic procedures, types of VTE and treatment were collected during hospitalization and scheduled outpatient visits.

Results: From 2005 to 2021, 5037 patients had consented for research in TROLL. Median age was 67 years (IQR 55-77) and 2622 (52.1%) were males. 2736 (54.3%) had pulmonary embolism (PE), 2034 (40.4%) had deep vein thrombosis (DVT), and 265 (5.3%) had upper extremity DVT, splanchnic or cerebral sinus vein thrombosis. 2330 (46.3%) were classified as unprovoked VTE whereas 1131 (22.5%) had cancer associated thrombosis. (Table) Direct oral anticoagulants were the most frequent treatment (39.3%) followed by low-molecular weight heparins (30.4%) and vitamin K antagonists (30.3%). Outpatient treatment of DVT increased from 71% in 2005 to 77% in 2019 whereas, outpatient treatment for PE increased from 4% in 2005 to 23% in 2019.

Conclusion(s): TROLL is a relatively large ongoing population-based registry of unselected VTE patients, with high-quality data that represent a valuable source of real-world data on the management and outcomes of VTE. The findings to date correspond well with those reported from other registries of unselected VTE patients. The long-term follow-up of patients in TROLL and linkage to other local and national registries, and local biobank provide unique opportunities for research on the management, biomarkers, risk factors and short- and long-term outcomes of VTE.